Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01045707 · ClinicalTrials.gov registry record · Phase 3
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
NCT01045707 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 530 participants.
The verdict
NCT01045707, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
Study Summary
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin glargine (IGlar), both as add-on to subject's ongoing treatment with metformin + at least one OAD (oral anti-diabetic drug). The main period is registered internally at Novo Nordisk as NN5401-3590 while the extension period is registered as NN5401-3726.
Interventions
- DRUG insulin glargine
- DRUG insulin degludec/insulin aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01045707
The ClinicalTrials.gov registry entry for NCT01045707 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin glargine is the first listed.
NCT01045707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01045707 about?
NCT01045707 is a clinical study titled "Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes". This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin glargine (IGlar), both as add-on to subject's ongoing treatment with metformin + at least one...
What is the current status of trial NCT01045707?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2010-01. Estimated completion is 2010-10.
What interventions are being tested in trial NCT01045707?
The interventions under investigation include: insulin glargine (DRUG), insulin degludec/insulin aspart (DRUG).
Who is sponsoring clinical trial NCT01045707?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.